Physician profile
Joseph Sleiman
NPI 1649765744
$2,610.97
in general payments reported to CMS, 2019-2025
15 companies · $631 in 2025
The $631 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $102 · 2021: $321 · 2022: $553 · 2023: $390 · 2024: $614 · 2025: $631.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,555 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,554.70 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $687.27 | 2024-2025 | Tremfya, Stelara |
| Abbvie INC. | $506.93 | 2022-2023 | Rinvoq |
| Takeda Pharmaceuticals U.S.A., INC. | $363.90 | 2021-2022 | |
| Boston Scientific Corporation | $299.40 | 2020-2025 | Lux-Dx Insertable Cardiac Monitor |
| Gilead Sciences, INC. | $103.89 | 2024 | Epclusa |
| Lilly USA, LLC | $103.40 | 2025 | Omvoh |
| Ferring Pharmaceuticals INC. | $99.54 | 2023 | Rebyota |
| Medtronic, INC. | $91.26 | 2022 | |
| Johnson & Johnson Health Care Systems INC. | $82.50 | 2024 | Stelara |
| E.R. Squibb & Sons, L.L.C. | $63.36 | 2024 | |
| Bridgebio Pharma, INC. | $63.34 | 2025 | Attruby |
| Pfizer INC. | $46.85 | 2025 | |
| Genzyme Corporation | $43.74 | 2025 | |
| Davol INC. | $32.40 | 2025 | Arista |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $23.19 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Sleiman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.